Skip to main content
SpringerLink
Log in

Carcinome hypophysaire

  • Chapter
Tumeurs malignes rares

Résumé

Les adénomes hypophysaires développés aux dépens des cellules antéhypophysaires sont l’une des tumeurs intracrâniennes les plus fréquentes chez l’adulte. Leur incidence serait de 15,5/million/ an, avec une prévalence estimée à 0,02 voire 0,1 % selon certains auteurs (1, 2). Ces tumeurs sont classées d’après le type cellulaire d’origine en adénomes somatotropes, à prolactine, corticotrope, thyréotrope, gonadotrope ou non immunoréactif; ce dernier type est encore appelé non sécrétant ou non fonctionnel. Les tumeurs hypophysaires, en majorité non invasives, avec un développement limité à la selle turcique, sont considérées comme bénignes. Toutefois, 45 à 55 % de ces tumeurs, selon les critères utilisés, sont invasives et peuvent infiltrer le sinus sphénoïdal, les sinus caverneux, la dure-mère, l’os et/ou les tissus avoisinants (3). Certaines de ces tumeurs (10–20 % environ) ont une vitesse de croissance rapide et des signes histologiques particuliers, les faisant considérer comme des « adénomes bénins atypiques » ou «agressifs».

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Daly AF, Rixhon M, Adam C, et al. (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91: 4769–75

    Article  CAS  PubMed  Google Scholar 

  2. Ezzat S, Asa SL, Couldwell WT, et al. (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101: 613–9

    Article  PubMed  Google Scholar 

  3. Meij BP, Lopes MB, Ellegala DB, et al. (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96: 195–208

    Article  PubMed  Google Scholar 

  4. Scheithauer B, Kovacs K, Horvath E, et al. (2004) Pituitary carcinoma. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds.), World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press: Lyon

    Google Scholar 

  5. Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurgery Focus 16: E7

    Google Scholar 

  6. Kaltsas GA, Mukherjee JJ, Plowman PN, et al. (1998) The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 83: 4233–8

    Article  CAS  PubMed  Google Scholar 

  7. Kaltsas GA, Nomikos P, Kontogeorgos G, et al. (2005) Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90: 3089–99

    Article  CAS  PubMed  Google Scholar 

  8. Pernicone PJ, Scheithauer B, Sebo TJ, et al. (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79: 804–12

    Article  CAS  PubMed  Google Scholar 

  9. Beauchesne P, Trouillas J, Barral F, Brunon J (1995) Gonadotropic pituitary carcinoma: case report. Neurosurgery 37: 810–5

    Article  CAS  PubMed  Google Scholar 

  10. Gurlek A, Karavitaki N, Ansorge O, Wass JA (2007) What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156: 143–53

    Article  CAS  PubMed  Google Scholar 

  11. Landman RE, Horwitz M, Peterson RE, et al. (2002) Longterm survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature. J Clin Endocrinol Metab 87: 3084–99

    Article  CAS  PubMed  Google Scholar 

  12. Delgrange E, Trouillas J, Maiter D, et al. (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82: 2102–7

    Article  CAS  PubMed  Google Scholar 

  13. McCormick PC, Post KD, Kandji AD, Hays AP (1989) Metastatic carcinoma to pituitary gland. Br J Neurosurg 3: 71–9

    Article  CAS  PubMed  Google Scholar 

  14. Knosp E, Kitz K, Perneczky A, et al. (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25: 927–30

    Article  CAS  PubMed  Google Scholar 

  15. Thapar K, Kovacs K, Scheithauer BW, et al. (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–106

    Article  CAS  PubMed  Google Scholar 

  16. Hsu DW, Hakim F, Biller BM, et al. (1993) Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78: 753–61

    Article  CAS  PubMed  Google Scholar 

  17. Simpson DJ, Fryer AA, Grossman AB, et al. (2001) Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas. Carcinogenesis 22: 1801–7

    Article  CAS  PubMed  Google Scholar 

  18. Zhang X, Horwitz GA, Heaney AP, et al. (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84:761–7

    Article  CAS  PubMed  Google Scholar 

  19. Thapar K, Scheithauer BW, Kovacs K, et al. (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38: 765–70

    Article  CAS  PubMed  Google Scholar 

  20. Turner HE, Nagy Z, Esiri MM, et al. (2000) Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab 85: 2931–5

    Article  CAS  PubMed  Google Scholar 

  21. Shimon I, Hinton DR, Weiss MH, Melmed S (1998) Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness. Clin Endocrinol (Oxf) 48: 23–9

    Article  CAS  Google Scholar 

  22. Lloyd RV, Vidal S, Horvath E, et al. (2003) Angiogenesis in normal and neoplastic pituitary tissues. Microsc Res Tech 60: 244–50

    Article  CAS  PubMed  Google Scholar 

  23. Saeger W, Lubke D (1996) Pituitary Carcinomas. Endocr Pathol 7: 21–35

    Article  CAS  PubMed  Google Scholar 

  24. Wierinckx A, Auger C, Devauchelle P, et al. (2007) A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer 14: 887–900

    Article  CAS  PubMed  Google Scholar 

  25. Komninos J, Vlassopoulou V, Protopapa D, et al. (2004) Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 89: 574–80

    Article  CAS  PubMed  Google Scholar 

  26. Bret P, Jouvet A, Madarassy G, et al. (2001) Visceral cancer metastasis to pituitary adenoma: report of two cases. Surg Neurol 55: 284–90

    Article  CAS  PubMed  Google Scholar 

  27. Walker JD, Grossman A, Anderson JV, et al. (1993) Malignant prolactinoma with extracranial metastases: a report of three cases. Clin Endocrinol (Oxf) 38: 411–9

    Article  CAS  Google Scholar 

  28. Delgrange E, Sassolas G, Perrin G, et al. (2005) Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien) 147: 751–7

    Article  CAS  Google Scholar 

  29. Stewart PM, Carey MP, Graham CT, et al. (1992) Growth hormone secreting pituitary carcinoma: a case report and literature review. Clin Endocrinol (Oxf) 37: 189–94

    Article  CAS  Google Scholar 

  30. Kaltsas GA, Mukherjee JJ, Isidori A, et al. (2002) Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol (Oxf) 57:169–83

    Article  CAS  Google Scholar 

  31. Lim S, Schahinian H, Maya MM, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncology 7: 518–20

    Article  PubMed  Google Scholar 

  32. Karga HJ, Alexander JM, Hedley-Whyte ET, et al. (1992) Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 74: 914–9

    Article  CAS  PubMed  Google Scholar 

  33. Cai WY, Alexander JM, Hedley-Whyte ET, et al. (1994) Ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab 78:89–93

    Article  CAS  PubMed  Google Scholar 

  34. Woloschak M, Roberts JL, Post K, et al. (1994) c-myc, cfos, and c-myb gene expression in human pituitary adenomas. J Clin Endocrinol Metab 79: 253–7

    Article  CAS  PubMed  Google Scholar 

  35. Rickert CH, Scheithauer BW, Paulus W, et al. (2001) Chromosomal aberrations in pituitary carcinoma metastases. Acta Neuropathol 102: 117–20

    CAS  PubMed  Google Scholar 

  36. Vierimaa O, Georgitsi M, Lehtonen R, et al. (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312: 1228–30

    Article  CAS  PubMed  Google Scholar 

  37. Marx SJ, Agarwal SK, Kester MB, et al. (1998) Germline and somatic mutation of the gene for multiple endocrine neoplasia type 1 (MEN1). J Intern Med 243: 447–53

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire d’histologie et embryologie moléculaires INSERM U842 Faculté de médecine Lyon-Est, Université Lyon I, Rue Guillaume-Paradin, 69372, Lyon Cedex 08

    Jacqueline Trouillas, Gérald Raverot & Carole Auger

  2. Centre de pathologie Est, Groupement hospitalier Est, 59, boulevard Pinel, 69677, Bron

    Jacqueline Trouillas, Gérald Raverot & Emmanuel Jouanneau

  3. Service de neurochirurgie A et C, Groupement hospitalier Est, 59, Boulevard Pinel, 69677, Bron

    Emmanuel Jouanneau

Authors
  1. Jacqueline Trouillas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gérald Raverot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emmanuel Jouanneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carole Auger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Trouillas, J., Raverot, G., Jouanneau, E., Auger, C. (2010). Carcinome hypophysaire. In: Tumeurs malignes rares. Springer, Paris. https://doi.org/10.1007/978-2-287-72070-3_71

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-72070-3_71

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-72069-7

  • Online ISBN: 978-2-287-72070-3

Publish with us

Policies and ethics

Search

Navigation